PSTV Plus Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
09:09
Jan 05
Jan 05
Long PSTV on CNSide revenue plus REYOBIQ FDA catalyst.
The author argues Plus Therapeutics is undervalued because CNSide is already generating revenue in 120+ cancer centers and now has national Humana and UnitedHealthcare coverage, making the $76M market cap look low. REYOBIQ's 75% clinical benefit rate and a constructive FDA meeting create a near-term catalyst via an expected pivotal trial roadmap. Insider buying by the CEO and CFO, plus BlackRock and Vanguard positions, are cited as smart-money confirmation. The main stated risk is Nasdaq's $1.00 minimum bid compliance by May, while cash is estimated to last into late 2026.
HIGH
About PSTV Investor Commentary
Across the available history and selected sources, Buzzberg tracks PSTV (Plus Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/kvmcc.